CSI Market
Sign In | Register

Relmada Therapeutics Inc (RLMD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RLMD Annual Cash Flow →
This cash flow overview for Relmada Therapeutics Inc spans from Mar 31 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-31.97
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation1.97
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Common Stock Issued For Services-
Fair Value Of Derivatives Issued In Connection With Issuance Of Preferred Stock-
Financing Of Note Payable-
Gain On Lease Assignment-
Derivative Gain Loss On Derivative Net-
Stock Appreciation Rights Compensation2.68
Issuance Of Restricted Common Stock-
Income taxes0.00
Realized Investment Gains (Losses), Total-0.75
Increase (Decrease) in Other Receivables0.01
Increase (Decrease) in Accounts Payable0.84
Increase (Decrease) in Accrued Liabilities0.15
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.32
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.76
Discontinued operations0.00
Net Cash flow from Operating Activities-24.67
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds-117.64
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-117.64
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock150.15
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Deferred Offering Costs-
Proceeds From Subordinated Promissory Notes Net Of Deferred Financing Costs-
Proceeds From Sale Of Common Stock To Founder-
Unit Funds Received-
Warrants Exercised For Stock-
Cashless Eexercise Of Warrants-
Noncash Or Part Noncash Acquisition Payables Assumed-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Payment Of Fees For Warrants Issued For Common Stock-
A T M Fee-
A T M Fees-
Conversion Of Stock Amount Converted-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents3.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities150.15
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-24.67
Total Cash Flow7.84
4 historic quarters locked

Sign in to unlock the full Relmada Therapeutics Inc cash flow history.

Sign In Create Free Account

About Relmada Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-086151

Figures are derived from filed reports and may be restated. Historical data is subject to revision.